Mid Atlantic Permanente Medical Group, Baltimore, Maryland.
Centers for Disease Control and Prevention, Atlanta, Georgia.
J Urol. 2017 Apr;197(4):1121-1126. doi: 10.1016/j.juro.2016.10.063. Epub 2016 Oct 24.
Although testosterone replacement therapy use in the United States has increased dramatically in the last decade, to our knowledge trends in testosterone replacement therapy use among reproductive-age men have not been investigated. We assessed changes in testosterone replacement therapy use and practice patterns among 18 to 45-year-old American men from 2003 to 2013 and compared them to older men.
This is a retrospective, cross-sectional analysis of men 18 to 45 and 56 to 64 years old who were enrolled in the Truven Health MarketScan® Commercial Claims Databases throughout each given calendar year from 2003 to 2013, including 5,094,868 men in 2013. Trends in the yearly rates of testosterone replacement therapy use were calculated using Poisson regression. Among testosterone replacement therapy users, the Cochran-Armitage test was used to assess temporal trends in age, formulation type, semen analysis and serum testosterone level testing during the 12 months preceding the documented use of testosterone replacement therapy.
Between 2003 and 2013, there was a fourfold increase in the rate of testosterone use among 18 to 45-year-old men from 29.2/10,000 person-years to 118.1/10,000 person-years (p <0.0001). Among testosterone replacement therapy users, topical gel formulations were initially most used. Injection use then doubled between 2009 and 2012 (23.5% and 46.2%, respectively) and surpassed topical gel use in 2013. In men 56 to 64 years old there was a statistically significant threefold increase in testosterone replacement therapy use (p <0.0001), which was significantly smaller than the fourfold increase in younger men (p <0.0001).
In 2003 to 2013, testosterone replacement therapy use increased fourfold in men 18 to 45 years old compared to threefold in older men. This younger age group should be a focus for future studies due to effects on fertility and unknown long-term sequelae.
尽管美国在过去十年中接受睾丸激素替代疗法治疗的人数显著增加,但据我们所知,尚未研究生殖年龄段男性使用睾丸激素替代疗法的趋势。我们评估了 2003 年至 2013 年期间 18 至 45 岁美国男性中睾丸激素替代疗法的使用情况和治疗模式,并与老年男性进行了比较。
这是一项对 18 至 45 岁和 56 至 64 岁的男性进行的回顾性、横断面分析,他们在 2003 年至 2013 年期间参加了 Truven Health MarketScan®商业索赔数据库,2013 年共有 5094868 名男性。使用泊松回归计算睾丸激素替代疗法每年使用率的趋势。在睾丸激素替代疗法使用者中,使用 Cochran-Armitage 检验评估在记录使用睾丸激素替代疗法之前的 12 个月内,年龄、制剂类型、精液分析和血清睾丸激素水平检测的时间趋势。
在 2003 年至 2013 年间,18 至 45 岁男性的睾丸激素使用率从 29.2/10000 人年增加到 118.1/10000 人年,增加了四倍(p<0.0001)。在睾丸激素替代疗法使用者中,最初最常使用的是局部凝胶制剂。在 2009 年至 2012 年期间,注射使用量增加了一倍(分别为 23.5%和 46.2%),并在 2013 年超过了局部凝胶的使用量。56 至 64 岁的男性睾丸激素替代疗法的使用率增加了三倍,具有统计学意义(p<0.0001),但低于年轻男性的四倍增长(p<0.0001)。
在 2003 年至 2013 年期间,18 至 45 岁男性的睾丸激素替代疗法使用率增加了四倍,而 56 至 64 岁男性的使用率增加了三倍。由于对生育能力的影响和未知的长期后果,这个年轻的年龄组应该是未来研究的重点。